Publications

Detailed Information

Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas

DC Field Value Language
dc.contributor.authorYang, Seung-Heon-
dc.contributor.authorKim, Yong Hwy-
dc.contributor.authorKim, Jin Wook-
dc.contributor.authorPark, Chul-Kee-
dc.contributor.authorJung, Hee-Won-
dc.contributor.authorPark, Sung-Hye-
dc.date.accessioned2012-05-31T00:22:01Z-
dc.date.available2012-05-31T00:22:01Z-
dc.date.issued2009-10-
dc.identifier.citationJOURNAL OF KOREAN NEUROSURGICAL SOCIETY; Vol.46 4; 385-388ko_KR
dc.identifier.issn2005-3711-
dc.identifier.urihttps://hdl.handle.net/10371/76633-
dc.description.abstractObjective : We analyzed the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter in World Health Organization (WHO) grade III gliomas in association with other molecular markers to evaluate their prevalence. Methods : The samples of a total of 36 newly WHO grade III glioma patients including 19 anaplastic oligodendrogliomas (AO), 7 anaplastic oligoastrocytomas (AOA), and 10 anaplastic astrocytomas (AA) were analyzed. The methylation status of the MGMT gene promoter was confirmed by methylation-specific polymerase chain reaction. The 1p/19q chromosomal deletion status and EGFR amplification were assessed by Fluorescence In-Situ Hybridization. MGMT, EGFR, EGFRvIII, and p53 expression were analyzed by immunohistochemical staining. Results : The MGMT gene promoter was methylated in 32 (88.9%) and unmethylated in 4 (11.2%). Among them, all of the AO and AOA had methylated MGMT gene promoter without exception. Significant associations between MGMT gene promoter hypermethylation and 1p/19q deletion was observed (p = 0.003). Other molecular markers failed to show significant associations between MGMT gene promoter statuses. Conclusion : There was extensive epigenetic silencing of MGMT gene in high grade gliomas with oligodendroglial component. Together with frequent 1p/19q co-deletion in oligodendroglial tumors, this may add plausible explanations supporting the relative favorable prognosis in oligodendroglial tumors compared with pure astrocytic tumors.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN NEUROSURGICAL SOCko_KR
dc.subjectMGMT gene promoterko_KR
dc.subjectMethylation-specific PCRko_KR
dc.subjectOligodendrogliomako_KR
dc.subjectMethylationko_KR
dc.subject1p/19qko_KR
dc.titleMethylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomasko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor양승훈-
dc.contributor.AlternativeAuthor김용휘-
dc.contributor.AlternativeAuthor김진욱-
dc.contributor.AlternativeAuthor박철기-
dc.contributor.AlternativeAuthor박성혜-
dc.contributor.AlternativeAuthor정희원-
dc.identifier.doi10.3340/jkns.2009.46.4.385-
dc.citation.journaltitleJOURNAL OF KOREAN NEUROSURGICAL SOCIETY-
dc.description.citedreferenceKuo LT, 2009, INT J CANCER, V124, P2872, DOI 10.1002/ijc.24303-
dc.description.citedreferenceScheithauer BW, 2008, BRAIN PATHOL, V18, P307, DOI 10.1111/j.1750-3639.2008.00179.x-
dc.description.citedreferencevan den Bent MJ, 2007, J NEUROPATH EXP NEUR, V66, P1074-
dc.description.citedreferenceLouis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4-
dc.description.citedreferenceLavon I, 2007, CLIN CANCER RES, V13, P1429, DOI 10.1158/1078-0432.CCR-06-2050-
dc.description.citedreferenceJeon YK, 2007, NEUROPATHOLOGY, V27, P10, DOI 10.1111/j.1440-1789.2006.00735.x-
dc.description.citedreferenceHegi ME, 2005, NEW ENGL J MED, V352, P997-
dc.description.citedreferenceMollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575-
dc.description.citedreferencePaz MF, 2004, CLIN CANCER RES, V10, P4933-
dc.description.citedreferenceAlonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7-
dc.description.citedreferenceBalana C, 2003, CLIN CANCER RES, V9, P1461-
dc.description.citedreferenceKleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215-
dc.description.citedreferenceKLEIHUES P, 2002, J NEUROPATHOL EXP NE, V61, P226-
dc.description.citedreferenceDong SM, 2001, J NEUROPATH EXP NEUR, V60, P808-
dc.description.citedreferenceEsteller M, 2000, NEW ENGL J MED, V343, P1350-
dc.description.citedreferenceNutt CL, 2000, CANCER RES, V60, P4812-
dc.description.citedreferenceEsteller M, 1999, CANCER RES, V59, P793-
dc.description.citedreferenceKLEIHUES P, 1993, BRAIN PATHOL, V3, P255-
dc.description.citedreferencePEGG AE, 1990, CANCER RES, V50, P6119-
dc.description.tc3-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share